Search research articles
Contact Us
Filters
Showing results (111-120 of 166) with videos related to
Page
of 17
Sort By:
European Urology
|
July 27, 2007
Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder
Christopher Chapple, Philip Van Kerrebroeck, Andrea Tubaro, et al.
European Urology
|
July 18, 2017
Reply from Authors re: Mikkel Fode, Jens Sønksen. Towards a Greater Understanding of Underactive Bladder. Eur Urol 2017;72:408-9
Alan D Uren, Nikki Cotterill, Christopher Harding, et al.
The Journal of Urology
|
October 19, 2010
Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial
Roger Dmochowski, Christopher Chapple, Victor W Nitti, et al.
European Urology
|
October 9, 2018
Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms
Maurizio Serati, Karl-Erik Andersson, Roger Dmochowski, et al.
Neurourology and Urodynamics
|
October 14, 2020
Treatment decision-making among men with lower urinary tract symptoms: A qualitative study of men's experiences with recommendations for patient-centred practice
Lucy E Selman, Clare Clement, Cynthia A Ochieng, et al.
European Urology
|
August 17, 2019
Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment
Christian Gratzke, Christopher Chapple, Elizabeth R Mueller, et al.
Neurourology and Urodynamics
|
January 24, 2018
Development of an overactive bladder assessment tool (BAT): A potential improvement to the standard bladder diary
Con Kelleher, Christopher Chapple, Nathan Johnson, et al.
European Urology
|
April 24, 2013
OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial
Christopher Chapple, Karl-Dietrich Sievert, Scott MacDiarmid, et al.
World Journal of Urology
|
August 26, 2025
Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes
Benoit Peyronnet, Benjamin M Brucker, Cosimo De Nunzio, et al.
World Journal of Urology
|
November 3, 2025
Correction to: Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes
Benoit Peyronnet, Benjamin M Brucker, Cosimo De Nunzio, et al.
Page
of 17
Search research articles
Search
Showing results (111-120 of 166) with videos related to
Sort By:
Page
of 17
European Urology
|
July 27, 2007
Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder
Christopher Chapple, Philip Van Kerrebroeck, Andrea Tubaro, et al.
European Urology
|
July 18, 2017
Reply from Authors re: Mikkel Fode, Jens Sønksen. Towards a Greater Understanding of Underactive Bladder. Eur Urol 2017;72:408-9
Alan D Uren, Nikki Cotterill, Christopher Harding, et al.
The Journal of Urology
|
October 19, 2010
Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial
Roger Dmochowski, Christopher Chapple, Victor W Nitti, et al.
European Urology
|
October 9, 2018
Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms
Maurizio Serati, Karl-Erik Andersson, Roger Dmochowski, et al.
Neurourology and Urodynamics
|
October 14, 2020
Treatment decision-making among men with lower urinary tract symptoms: A qualitative study of men's experiences with recommendations for patient-centred practice
Lucy E Selman, Clare Clement, Cynthia A Ochieng, et al.
European Urology
|
August 17, 2019
Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment
Christian Gratzke, Christopher Chapple, Elizabeth R Mueller, et al.
Neurourology and Urodynamics
|
January 24, 2018
Development of an overactive bladder assessment tool (BAT): A potential improvement to the standard bladder diary
Con Kelleher, Christopher Chapple, Nathan Johnson, et al.
European Urology
|
April 24, 2013
OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial
Christopher Chapple, Karl-Dietrich Sievert, Scott MacDiarmid, et al.
World Journal of Urology
|
August 26, 2025
Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes
Benoit Peyronnet, Benjamin M Brucker, Cosimo De Nunzio, et al.
World Journal of Urology
|
November 3, 2025
Correction to: Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes
Benoit Peyronnet, Benjamin M Brucker, Cosimo De Nunzio, et al.
Page
of 17